David Perlmutter

TSPO PET imaging can detect activated microglia in living humans.

"We now see that we can, research-wise anyway, image the brain in living humans using what's called a TSPO scan. This scan images when the microglia are activated to their destructive state." (said at 0:04:49)

TSPO (18 kDa translocator protein) PET imaging is widely used in living human research to visualize neuroinflammation and microglial activation in vivo. However, the claim requires two important qualifications: first, TSPO is not exclusive to microglia, as it is also expressed by reactive astrocytes and constitutively by vascular endothelial cells; second, elevated TSPO signal reflects overall cellular upregulation/density and does not specifically distinguish a purely 'destructive' phenotype from other states of microglial activation or repair.

• context: Cellular sources of TSPO expression in healthy and diseased brain. (European journal of nuclear medicine and molecular imaging 2021) · cited 200x in the literature

  "TSPO binding, as measured with positron emission tomography (PET), is considered an in vivo marker of neuroinflammation. Indeed, TSPO expression is altered in neurodegenerative, neuroinflammatory, and neuropsychiatric diseases. In PET studies, the TSPO signal is often viewed as a marker of microglial cell activity. However, there is little evidence in support of a microglia-specific TSPO expression." (abstract, background, passage verified)

  pubmedfull study (doi)
• context: PET imaging of neuroinflammation: any credible alternatives to TSPO yet? (Molecular psychiatry 2025) · cited 40x in the literature

  "A key driver for this trend was the ability to image brain inflammation in vivo using PET radioligands targeting the Translocator Protein 18 kDa (TSPO), which is known to be expressed in activated microglia and astrocytes upon inflammatory events as well as constitutively in endothelial cells. TSPO is a mitochondrial protein that is expressed mostly by microglial cells upon activation but is also expressed by astrocytes in some conditions and constitutively by endothelial cells." (abstract, background)

  pubmedfull study (doi)

Being heterozygous for the APOE4 allele confers a five-fold increased risk of Alzheimer's disease, and being homozygous increases the risk 12-fold.

"if I'm heterozygous I have a five-fold increased risk. If I have two of them, homozygous, my risk for Alzheimer's may increase 12-fold." (said at 0:32:28)

Large meta-analyses establish that carrying APOE ε4 significantly increases the risk of Alzheimer's disease in a dose-dependent manner. In Caucasian populations compared to ε3/ε3 individuals, heterozygosity (ε3/ε4) is associated with an approximate 3-fold increased risk (odds ratio ~3.2, 95% CI 2.8–3.8, though reaching ~5.6 in Japanese cohorts), while homozygosity (ε4/ε4) increases risk approximately 12- to 15-fold (OR ~14.9 in Caucasians, 95% CI 10.8–20.6). The speaker's figures of 5-fold and 12-fold closely reflect this well-established gene-dose effect, with exact odds ratios varying somewhat by ancestral background, sex, and age.

• supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4674x in the literature

  "Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6)" (abstract, results, passage verified)

  pubmed

A prospective study following 1,111 individuals over 12.7 years found that consuming an average of one serving of ultra-processed food per day was associated with a 13% increased risk of Alzheimer's disease.

"one study that was published in the Journal of Prevention of Alzheimer's—can you imagine, a Journal of Prevention of Alzheimer's? Be still my beating heart. And this study that came out last year followed a group of 1,111 individuals over a period of 12.7 years and basically asked these folks during this 12.7 year, during the period of time that we're going to study you, what do you eat? So they kept a food frequency diary. What did they find? They found that those individuals who consumed as an average one serving per day of ultra-processed foods experienced a 13% increased risk of Alzheimer's disease." (said at 0:51:55)

A prospective study from the Framingham Heart Study published in The Journal of Prevention of Alzheimer's Disease (follow-up mean 12.7 years) did find that each additional serving per day of ultra-processed food was associated with a 13% higher risk of Alzheimer's disease (HR = 1.13, 95% CI: 1.03–1.25). However, this finding was specific to participants who were younger than 68 years at baseline; no significant association was observed among individuals aged 68 or older at baseline.

• context: Ultra-processed food consumption and risk of dementia and Alzheimer's disease: The Framing… (The journal of prevention of Alzheimer's disease 2025) · cited 22x in the literature

  "Among participants who were <68 years of age at baseline, each serving per day of ultra-processed food was associated with 13 % increased risk for Alzheimer's disease (HR = 1.13, 95 % CI:1.03-1.25)... no significant findings were observed when age at baseline was 68 years or above." (abstract, results)

  pubmedfull study (doi)

In the same prospective study, consuming 10 or more servings of ultra-processed foods per day was associated with a 270% increased risk of Alzheimer's disease.

"they found that in those individuals who consumed 10 or more servings of ultra-processed foods a day... Their risk is increased 270%. That's of a disease for which we have no meaningful pharmaceutical treatment." (said at 0:52:55)

The claim accurately reflects findings from an analysis of the Framingham Heart Study Offspring cohort published in 2025 (PMID: 39863327), but requires two qualifications: 1) An adjusted hazard ratio of 2.71 represents a 2.7-fold risk (a 171% relative increase), which is often conflated with a 270% increase; and 2) this association was observed exclusively in the subgroup of participants aged <68 years at baseline (HR 2.71, 95% CI 1.18–6.24), with no significant association detected among those aged ≥68 years.

• supports: Ultra-processed food consumption and risk of dementia and Alzheimer's disease: The Framing… (The journal of prevention of Alzheimer's disease 2025) · cited 22x in the literature

  "Among participants who were <68 years of age at baseline, each serving per day of ultra-processed food was associated with 13 % increased risk for Alzheimer's disease (HR = 1.13, 95 % CI:1.03-1.25), and consumption of ≥10 servings/day vs. <10 servings/day of ultra-processed food was associated with a 2.7-fold increase in Alzheimer's disease risk (HR = 2.71, 95 % CI:1.18-6.24), after adjustment for age, sex, education, total energy, metabolic factors and diet quality." (abstract, results)

  pubmedfull study (doi)

Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.

"Paraquat is used experimentally to create Parkinson's in primates in research laboratories" (said at 0:59:42)

Paraquat is widely used in laboratory research as a neurotoxin to model Parkinson's disease (PD) mechanisms and dopaminergic degeneration, and it has been administered to non-human primates in experimental research assessing striatal dopaminergic deficits. However, the claim requires qualification: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the standard and predominant neurotoxin used to create full parkinsonian syndromes in non-human primates, whereas paraquat is primarily utilized in rodent and in vitro cellular models of PD.

• context: Neural repair strategies for Parkinson's disease: insights from primate models. (Cell transplantation 2006) · cited 53x in the literature

  "In particular, discussion addresses the 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydopyridine (MPTP), rotenone, paraquat, and maneb parkinsonian models." (abstract, passage verified)

  pubmedfull study (doi)
• supports: Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum. (The Journal of pharmacology and experimental therapeutics 2008) · cited 11x in the literature

  "Because nonhuman primates are evolutionarily closer to humans and may better model the effects of pesticide exposure in man, we examined the effects of paraquat on striatal nAChR function and expression in monkeys. Monkeys were administered saline or paraquat once weekly for 6 weeks, after which nAChR levels and receptor-evoked [(3)H]dopamine ([(3)H]DA) release were measured in the striatum." (abstract, methods, passage verified)

  pubmedfull study (doi)
• context: Neurotoxin-based models of Parkinson's disease. (Neuroscience 2012) · cited 513x in the literature

  "The 6-OHDA rat model and the MPTP primate model have contributed enormously to translate animal experimentation into clinical practice, including pharmacological treatments and deep brain stimulation of the subthalamic nucleus... The more recently developed paraquat and rotenone rodent models are also contributing to our understanding of neuronal cell death." (abstract, passage verified)

  pubmedfull study (doi)

Systemic inflammation causes microglia to polarize into a pro-inflammatory M1 phenotype that releases damaging cytokines, creating a feed-forward cycle that activates further microglia.

"inflammation from any source will shift the microglia to becoming their M1 destructive phenotype, we call it. That is a pro-inflammatory phenotype, meaning that once those microglia shift to being the evil twin... they are spitting out more and more of these damaging cytokines in the brain that further target other good microglia cells and shift them to being on the dark side" (said at 1:02:52)

The claim captures the traditional paradigm of neuroinflammation—where systemic inflammatory signals trigger microglial activation, cytokine release, and self-propagating neuroinflammatory cascades—but frames it using an outdated, oversimplified binary model. While preclinical and clinical studies confirm that peripheral inflammation promotes pro-inflammatory microglial responses and cytokine cascades, contemporary neuroscience (via single-cell transcriptomics and multi-omics) has discarded the strict binary 'M1 (destructive/pro-inflammatory) vs M2 (protective/anti-inflammatory)' classification. Microglia in vivo exhibit heterogeneous, multidimensional, and highly dynamic transcriptomic and functional states rather than a fixed 'M1 evil twin' switch.

• supports: The Role of Microglia in Perioperative Neuroinflammation and Neurocognitive Disorders. (Frontiers in aging neuroscience 2021) · cited 73x in the literature

  "The aseptic trauma of peripheral surgery activates a systemic inflammatory response that results in neuro-inflammation; the microglia, the resident immunocompetent cells in the brain, are a key element of the neuroinflammatory response... However, microglia have also been implicated in producing harm possibly by changing its phenotype from its beneficial, anti-inflammatory state (termed M2) into an injurious pro-inflammatory state (termed M1); it is likely that there are intermediates states between these polar phenotypes and some consider that a gradient exists with a number of intermediates, rather than a strict dichotomy between M1 and M2." (abstract, results, passage verified)

  pubmedfull study (doi)
• context: Microglial states revisited: from homeostasis to disease. (Nature reviews. Neuroscience 2026)

  "Advances in single-cell and single-nucleus transcriptomics, chromatin accessibility profiling, and spatial multi-omics have negated binary frameworks of 'resting versus activated' or 'M1 (pro-inflammatory) versus M2 (anti-inflammatory)' and revealed a multidimensional state space that supports brain development, homeostasis and adaptive responses to perturbation." (abstract, results, passage verified)

  pubmedfull study (doi)

Between 25% and 28% of people carry an MTHFR polymorphism.

"You know, it's interesting you mentioned B vitamins and methylated B vitamins for those of us, the 25 to 28% of us who have this MTHFR polymorphism." (said at 0:28:50)

The speaker's figure of 25% to 28% likely conflates allele frequency or specific homozygous/heterozygous subpopulations with the overall carrier rate. In reality, carrying at least one variant allele of the MTHFR gene (such as C677T or A1298C) is much more common, occurring in over 50% to 60% of many populations (and up to 87% across all variants). Conversely, homozygous inheritance for the most clinically discussed variant (C677T, genotype TT) varies widely by ancestry, from ~1% in populations of African descent to ~10–14% in non-Hispanic whites and ~20% or more in Hispanic populations. An allele frequency of ~25–35% is common for the 677T allele in certain groups, but referring to 25–28% of individuals as 'carrying' an MTHFR polymorphism is an imprecise representation of population genetics.

• context: 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE re… (American journal of epidemiology 2000) · cited 1054x in the literature

  "The population frequency of C677T homozygosity ranges from 1% or less among Blacks from Africa and the United States to 20% or more among Italians and US Hispanics." (abstract, results, passage verified)

  pubmedfull study (doi)
• context: Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of… (The American journal of clinical nutrition 2012) · cited 58x in the literature

  "The TT genotype frequency varied from 1.2% (95% CI: 0.7, 2.0) in non-Hispanic blacks and 11.6% (95% CI: 9.6, 14.0) in non-Hispanic whites to 19.4% (95% CI: 16.7, 22.3) in Mexican Americans." (abstract, results, passage verified)

  pubmedfull study (doi)

Circulating inflammatory cytokines cross the blood-brain barrier and polarize microglial cells away from supportive housekeeping states and toward destructive states.

"Well, the other thing is the fact that these inflammatory cytokines readily get through the blood-brain barrier and then influence the brain's immune cells, the microglia, to polarize them away from being supportive and towards being destructive." (said at 0:46:32)

The speaker accurately describes the downstream functional consequence—systemic inflammatory cytokines activate and shift microglia from homeostatic/supportive surveillance phenotypes toward reactive, neurotoxic phenotypes that exacerbate neuroinflammation and tissue damage. However, the claim that cytokines 'readily get through' the blood-brain barrier (BBB) requires qualification. Cytokines are large hydrophilic proteins (~15–25 kDa) that do not passively diffuse across an intact BBB; rather, they communicate with the central nervous system through specialized saturable transport systems, circumventricular organs, direct activation of brain endothelial cells (which transduce signals centrally), or when pathological systemic inflammation compromises BBB integrity.

• supports: Neuroimmune crosstalk in chronic neuroinflammation: microglial interactions and immune mod… (Frontiers in cellular neuroscience 2025) · cited 72x in the literature

  "Among CNS-resident cells, microglia play a central role, exhibiting a dynamic spectrum of phenotypes ranging from neuroprotective to neurotoxic. In chronic neurodegenerative diseases, sustained microglial activation often leads to the amplification of inflammatory cascades, reinforcing a pathogenic cycle of immune-mediated damage." (abstract, passage verified)

  pubmedfull study (doi)
• context: Peripheral Inflammation and Insulin Resistance: Their Impact on Blood-Brain Barrier Integr… (International journal of molecular sciences 2025) · cited 52x in the literature

  "Emerging evidence suggests that peripheral insulin resistance and chronic inflammation, often associated with type 2 diabetes (T2D) and obesity, promote increased proinflammatory cytokines, oxidative stress, and immune cell infiltration. These conditions further damage the blood-brain barrier (BBB) integrity and promote neurotoxicity and chronic glial cell activation." (abstract, passage verified)

  pubmedfull study (doi)

A 2018 study following 1,600 Japanese participants for 12 years found that individuals in the highest uric acid group had an 80% increased risk of all-cause dementia, a 55% increased risk of Alzheimer's, and a 166% increased risk of mixed/vascular dementia.

"there was an interesting study that was in, I think, 2018 of 1,600 Japanese that were followed for 12 years. They had neurocognitive exams every two years and many times they had MRI scans, and they found that dementia in general risk in the highest group of uric acid was increased 80%, and Alzheimer's per se increased 55%, and mixed dementia/vascular was increased 166% in those with the highest uric acid." (said at 0:15:32)

The speaker accurately describes the findings of a 2018 prospective cohort study (Latourte et al., PMID 28754803) involving 1,598 older adults followed over 12 years with brain MRI and cognitive assessments. The study found that individuals in the highest quartile of serum uric acid had an adjusted hazard ratio (HR) of 1.79 (~80% increased risk) for all-cause dementia, an HR of 1.55 (55% increased risk, though not statistically significant, p=0.10) for Alzheimer's disease, and an HR of 3.66 (a 266% increase, which the speaker stated as 166%) for vascular or mixed dementia. However, the study was conducted in Dijon, France (the Three-City Dijon cohort), not in Japan.

• partial: Uric acid and incident dementia over 12 years of follow-up: a population-based cohort stud… (Annals of the rheumatic diseases 2018) · cited 150x in the literature

  "The study sample comprised 1598 people (mean (SD) age 72.4(4.1) years, 38.3% male). During the 13,357 person-years of follow-up (median duration: 10.1 years), dementia developed in 110 participants (crude incidence rate: 8.2/1000 person-years). After multiple adjustments, the multivariate HR with the highest (≥75th percentile) versus lowest SUA level was 1.79 (95% CI 1.17 to 2.73; p=0.007). The association was stronger with vascular or mixed dementia (HR=3.66 (95% CI 1.29 to 10.41), p=0.015) than Alzheimer's disease (HR=1.55 (95% CI 0.92 to 2.61), p=0.10)." (abstract, results, passage verified)

  pubmedfull study (doi)